Vijaya Diagnostic Centre Limited Board Approves Key Executive Appointments and Q3 Financial Results
Vijaya Diagnostic Centre Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the Unaudited…
Black Box Limited Monitoring Agency Report for Q3 FY2026 on Preferential Issue Proceeds
Black Box Limited has submitted its Monitoring Agency Report for the quarter ending December 31, 2025, concerning the utilization of proceeds…
Indo Count Industries Limited Unaudited Financial Results for Q3 FY2026
Indo Count Industries Limited announced the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended…
Aarti Pharmalabs Clarification on Delayed Disclosure Event to Exchange
Aarti Pharmalabs has issued a formal clarification regarding the delay in submitting an event disclosure required within 24 hours. The company…
Vijaya Diagnostic Centre Unaudited Financial Results for Q3 FY2025-26 Approved
The Board of Directors of Vijaya Diagnostic Centre Limited approved the Unaudited Standalone and Consolidated Financial Results for the…
Ceigall India Limited Strong Q3 FY’26 Results Driven by Robust Order Inflow and Sector Momentum
Ceigall India Limited reported strong performance for Q3 FY’26, fueled by sustained government infrastructure spending. Standalone…
ALKEM LABORATORIES LTD Subsidiary Alkem MedTech Acquires Majority Stake in Swiss Medical Device Firm Occlutech
Alkem MedTech Pvt Ltd, a wholly-owned subsidiary of Alkem Laboratories, has announced the execution of a binding offer to acquire a majority…
BASF India Limited Announcement of Unaudited Financial Results for Q3 FY2025-26
BASF India Limited has announced its Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December…
Indo Count Industries Limited Board Approves Unaudited Financial Results for Q3 FY2026
Indo Count Industries Limited announced the approval of its Unaudited Standalone and Consolidated Financial Results for the quarter and nine…
Eris Lifesciences Strong Q3 FY26 Performance Driven by 10% DBF Growth and International Business Surge
Eris Lifesciences reported robust financial results for Q3 and 9M FY26, highlighted by 10% year-over-year growth in Domestic Branded…